Carla Marienfeld1, Pulin Liu2, Xia Wang3, Richard Schottenfeld1, Wang Zhou4, Marek C Chawarski5. 1. Yale School of Medicine, Department of Psychiatry, 34 Park Street, New Haven, CT 06519, United States. 2. Wuhan Centers for Disease Prevention and Control, 24 Jianghan North Road, Wuhan, PR China; Tongji Medical College, School of Public Health, Huazhong University of Science & Technology, 13 Hangkong Road, Wuhan, PR China. 3. Wuhan Centers for Disease Prevention and Control, 24 Jianghan North Road, Wuhan, PR China. 4. Wuhan Centers for Disease Prevention and Control, 24 Jianghan North Road, Wuhan, PR China. Electronic address: wzhou@whcdc.org. 5. Yale School of Medicine, Department of Psychiatry, 34 Park Street, New Haven, CT 06519, United States. Electronic address: marek.chawarski@yale.edu.
Abstract
BACKGROUND: Methadone maintenance treatment (MMT) reduces the harms of opioid use disorder and is being rapidly scaled-up in China. This study evaluated the real-world implementation of MMT system in Wuhan, China. METHODS: Data extracted from electronic medical records collected in 2010 on 8811 patients were used to compute for each patient indices of the prescribed and consumed daily methadone doses, an adherence index, dose adjustments following missed doses, the rates of opiate positive urine tests, self-reported drug use, injection drug use (IDU), and the duration of MMT exposure. FINDINGS: The modal daily doses prescribed were 60 mg and above for 68.5% of patients. Adherence was variable: 51% of patients attended less than 60% and 26% attended 80-100% of their treatment days; and patients with long MMT exposure had significantly higher adherence rates than patients with short MMT exposure. The differences between doses dispensed immediately before and after the interruption in dosing days ranged from 0 to 7 mg, independently of the length of the interruption or the prescribed dosing level. The overall rate of opiate positive tests was 20%; 45% of patients had at least one opiate positive test; 29% reported past month drug use and 53% of them reported past month IDU. Adherence and MMT exposure duration correlated significantly with the proportion of opiate negative urine tests (r=0.355, p<0.001; r=0.351, p<0.001, respectively). Treatment for males and females was comparable. CONCLUSIONS: Provision of safe methadone dosing after absences and improving daily attendance are identified as priority improvement areas.
BACKGROUND:Methadone maintenance treatment (MMT) reduces the harms of opioid use disorder and is being rapidly scaled-up in China. This study evaluated the real-world implementation of MMT system in Wuhan, China. METHODS: Data extracted from electronic medical records collected in 2010 on 8811 patients were used to compute for each patient indices of the prescribed and consumed daily methadone doses, an adherence index, dose adjustments following missed doses, the rates of opiate positive urine tests, self-reported drug use, injection drug use (IDU), and the duration of MMT exposure. FINDINGS: The modal daily doses prescribed were 60 mg and above for 68.5% of patients. Adherence was variable: 51% of patients attended less than 60% and 26% attended 80-100% of their treatment days; and patients with long MMT exposure had significantly higher adherence rates than patients with short MMT exposure. The differences between doses dispensed immediately before and after the interruption in dosing days ranged from 0 to 7 mg, independently of the length of the interruption or the prescribed dosing level. The overall rate of opiate positive tests was 20%; 45% of patients had at least one opiate positive test; 29% reported past month drug use and 53% of them reported past month IDU. Adherence and MMT exposure duration correlated significantly with the proportion of opiate negative urine tests (r=0.355, p<0.001; r=0.351, p<0.001, respectively). Treatment for males and females was comparable. CONCLUSIONS: Provision of safe methadone dosing after absences and improving daily attendance are identified as priority improvement areas.
Authors: Robert P Schwartz; Jerome H Jaffe; David A Highfield; Jason M Callaman; Kevin E O'Grady Journal: Drug Alcohol Depend Date: 2006-06-21 Impact factor: 4.492
Authors: Robert P Schwartz; David A Highfield; Jerome H Jaffe; Joseph V Brady; Carol B Butler; Charles O Rouse; Jason M Callaman; Kevin E O'Grady; Robert J Battjes Journal: Arch Gen Psychiatry Date: 2006-01
Authors: Maja Meise; Xi Wang; Marie-luise Sauter; Yan-ping Bao; Jie Shi; Zhi-min Liu; Lin Lu Journal: Acta Pharmacol Sin Date: 2009-04-06 Impact factor: 6.150
Authors: Ruihua Dong; Hongyun Wang; Dandan Li; Liwei Lang; Frank Gray; Yongzhen Liu; Celine M Laffont; Malcolm Young; Ji Jiang; Zeyuan Liu; Susan M Learned Journal: Drugs R D Date: 2019-09